Table 3.
MR Estimates for the Effect of Lowering PCSK9 on CAD and AD Risk
| Study | SNPs, n | Method | Odds Ratio | 95% CI | p |
|---|---|---|---|---|---|
| CAD | 2 | IVW | 0.57 | 0.36–0.89 | 0.01 |
| IGAP | 3 | IVW | 1.10 | 0.85–1.43 | 0.47 |
| MR Egger | 1.10 | 0.67–1.81 | 0.78 | ||
| MR Egger intercept test | 1.00 | 0.93–1.07 | 0.99 | ||
| Wtd median | 1.09 | 0.81–1.47 | 0.56 | ||
| PGC | 3 | IVW | 1.98 | 1.02–3.81 | 0.04 |
| MR Egger | 1.95 | 0.58–6.54 | 0.48 | ||
| MR Egger intercept test | 1.00 | 0.84–1.19 | 0.98 | ||
| Wtd median | 1.72 | 0.81–3.65 | 0.16 | ||
| AD meta‐analysis | 3 | IVW | 1.19 | 0.94–1.51 | 0.16 |
Odds ratios and 95% CIs are per halving of circulating PCSK9 concentrations.
AD = Alzheimer disease; CAD = coronary artery disease; CI = confidence interval; IGAP = International Genomics of Alzheimer's Project; IVW = inverse variance weighted; MR = Mendelian randomization; PGC = Psychiatric Genomics Consortium; SNP = single nucleotide polymorphism; Wtd = weighted.